Panion will not renew Letter of Intent with GeneQuine
The board of directors for Panion Animal Health AB decided at their meeting of 4 December 2017 to focus Panion’s efforts on the development of the epilepsy project. This means that we will no longer pursue the dialogue and cooperation with GeneQuine Biotherapeutics GmbH with regards to their veterinary gene therapy projects. The mutually agreed Letter of Intent will therefore not be sought renewed or extended upon expiry on the 31 December 2017. The decision was taken for business reasons with the aim to focus on the opportunities that best fit with Panion’s strategic plans and have the potential to create the best future value for Panion’s shareholders.
“Panion will continue to evaluate human medicines projects that may carry great potential for development in veterinary medicine” says Anja Holm, CEO of Panion.
Anja E. H. Holm, CEO
+ 45-22 94 66 00
Bolaget ska utveckla och kommersialisera genterapi för behandling av epilepsiliknande tillstånd hos hundar och andra djur, samt utveckla och kommersialisera andra veterinärmedicinska produkter och nya behandlingsformer som kan ge sjuka djur bättre livskvalitet.
Panion will develop and commercialize a gene therapy treatment for dogs with drug refractory epilepsy, and other new animal health products and treatments that improve the quality of life for animals suffering from chronic diseases.